22.01.2013 06:30
Bewerten
(0)

Essilor on Track to Achieve Revenue of €1.5 Billion in Fast-Growing Countries by 2015

Regulatory News:

Pursuing its strategy in fast-growing countries, Essilor (Paris:EI) has announced the creation of partnerships with local leaders in Colombia, Turkey and China – all key markets in the Company’s development plan.

In Colombia, a country with 50 million inhabitants where Essilor opened a sales subsidiary approximately one year ago, the Company has signed an agreement to acquire a 51% stake in Servi Optica, one of South America’s largest prescription laboratories. An Essilor distributor, through the Varilux® and Shamir lenses in Colombia, Servi Optica is the market’s leading distributor of ophthalmic lenses and generates revenue of around €29 million.

Servi Optica will leverage the Company’s expertise and technological backing to speed its development in this market, in which progressive and anti-reflective lenses enjoy considerable growth potential and where over one person out of three with vision impairment is in need of corrective eyewear. Servi Optica will also serve as a launch pad for the Andean countries of Peru, Venezuela, Ecuador and Bolivia, where Essilor does not yet operate. The transaction is subject to approval by Colombian competition authorities.

In Turkey, the Company has signed an agreement to acquire a majority stake in Isbir Optik, the market’s leading distributor of ophthalmic lenses with full-year revenue of around €15 million. Based in Ankara, Isbir has a large number of sales offices and distributors throughout the country, as well as a prescription laboratory equipped with digital surfacing and coating technologies. The company distributes BBGR lenses under its own brand as well as Nikon brand lenses.

With a population of 80 million, Turkey is one of the fast-growing countries in the Mediterranean basin. Following the partnerships created with Shamir, which has a subsidiary in the country, and with Ipek Optik and Opak, this new operation considerably strengthens Essilor’s multi-network strategy in this market of 25 million lenses, in which high-index, progressive and variable-tint lenses and other value-added products represent an important reservoir of growth. The partnership between Isbir and Essilor is subject to a certain number of conditions precedent, including notifying Turkish competition authorities about the transaction. It should be completed in second-quarter 2013.

In China, Essilor has strengthened its business model with the acquisition of a majority stake in Tianhong, the market’s leading distributor of ophthalmic lenses. Based in Dan Yang, Tianhong supplies corrective lenses featuring a wide array of materials and designs to national and regional chains, most of which are positioned in the mid-range segment and located in Tier 2 and Tier 3 cities. Tianhong generates around €19 million in revenue, much of it from products manufactured by Essilor Group companies.

The mid-range segment in China is still highly fragmented. Served by a large number of producers that do not have direct access to opticians, the segment creates differentiation more by consumer and distributor brands than by lens performance features. The partnership with Tianhong strengthens the value proposition of Essilor, which has emerged as a major driver of market consolidation capable of meeting consumer demand for innovative solutions.

In the future Tianhong will be able to source high-quality products from a greater number of partners within the Essilor Group in order to improve its offer and strengthen its positions with Chinese opticians. Tianhong, for example, will promote the offer of Seeworld, which recently opened a prescription laboratory with high-technology equipment to capture the powerful growth potential of custom-made lenses, which currently account for only 4% of unit sales in China.

They will continue to distribute all brands to push value-added product, including antireflective and mid-tier photohcromic lenses.

Essilor has also finalized two transactions in North Africa, another dynamic region in the Mediterranean basin. In Tunisia, Essilor completed the acquisition of Sivo, the market’s leading distributor, which also operates in Morocco, Algeria, Côte d’Ivoire, Cameron and Togo and generates approximately €7 million in revenue.

In Morocco, Essilor completed the acquisition of Movisia, a distributor of Nikon and Kodak brand lenses. With revenue of around €1 million, Movisia strengthens the local operations of the group created by L’N Optic, a distributor of Varilux® and Crizal® lenses, and Optiben, which markets the BBGR brand.

Commenting on these recent developments, Hubert Sagnières, Essilor’s Chairman and Chief Executive Officer, said: "Essilor is continuing to deploy its multi-network growth strategy in all its host countries, with the goal of stepping up the pace of distribution for all Company brands. I also want to acknowledge the launch in 2012 of operations in five countries1 that confirms Essilor’s goal of providing vision correction solutions for everyone. This ability to forge partnerships with local industry leaders while continuing to drive powerful organic growth has strengthened our objective of generating full-year revenue of €1.5 billion in fast-growing countries by 2015.”

In 2011, Essilor generated slightly more than €600 million in revenue in fast-growing countries, which corresponded to approximately 15% of total sales. In third-quarter 2012, these countries represented approximately 18% of consolidated revenue.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around €150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog™ and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of €4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

1 Côte d’Ivoire, Laos, Sri Lanka, Togo and Tunisia

Nachrichten zu Essilor S.A.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Essilor S.A.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
18.07.2017Essilor buyUBS AG
13.07.2017Essilor NeutralJP Morgan Chase & Co.
05.07.2017Essilor overweightMorgan Stanley
30.06.2017Essilor buyHSBC
30.06.2017Essilor NeutralGoldman Sachs Group Inc.
18.07.2017Essilor buyUBS AG
05.07.2017Essilor overweightMorgan Stanley
30.06.2017Essilor buyHSBC
08.05.2017Essilor OutperformCredit Suisse Group
20.04.2017Essilor overweightMorgan Stanley
13.07.2017Essilor NeutralJP Morgan Chase & Co.
30.06.2017Essilor NeutralGoldman Sachs Group Inc.
19.06.2017Essilor NeutralGoldman Sachs Group Inc.
26.04.2017Essilor NeutralGoldman Sachs Group Inc.
25.04.2017Essilor HoldS&P Capital IQ
29.11.2016Essilor International VerkaufenIndependent Research GmbH
29.07.2016Essilor International VerkaufenIndependent Research GmbH
21.10.2015Essilor International UnderweightMorgan Stanley
03.08.2015Essilor International UnderweightMorgan Stanley
24.07.2015Essilor International UnderweightMorgan Stanley

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Essilor S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die Top 5 der Medizin- und Pharmakonzerne mit großen Wachstumschancen!

Aktien aus dem Medizin- und Pharmabereich gehören neben den hochtechnologischen Konzernen wohl zu den schwierigsten Wertpapieren, die man an der Börse spielen kann. Die meisten Unternehmen, die auf diesem Feld unterwegs sind, bleiben über Jahre hin unprofitabel. Wir stellen im aktuellen Anlegermagazin fünf Aktien vor, bei denen große Wachstumschancen lauern könnten.
Anlegermagazin kostenlos erhalten

Heute im Fokus

DAX schließt deutlich leichter -- Dow verliert -- VW-, Daimler-, BMW-Aktien verlieren kräftig: Deutsche Autoindustrie soll sich abgesprochen haben -- BYD, Tesla, Microsoft, eBay im Fokus

Siemens und Bombardier verhandeln über Eisenbahn-Joint Venture. Gazprom darf mehr Gas nach Deutschland pumpen. S&P stellt Griechenland bessere Bonität in Aussicht. Apple will mit Chinesen Autobatterien bauen: Unerwartete Konkurrenz für Tesla? Bill Gross warnt vor einem möglichen Wirtschaftskollaps. Warum Exxon jetzt plötzlich zum Umweltfreund wird. Bitcoin zurück auf Rekordkurs. General Electric verdient im zweiten Quartal weniger. Erneuter Ether-Diebstahl schreckt die Branche auf.

Top-Rankings

KW 29: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten
Sorglos die Koffer packen
In diesen europäischen Ländern kommt man voll auf seine Kosten
KW 28: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten

Die 5 beliebtesten Top-Rankings

Enormer Stressfaktor
In diesen Ländern haben Arbeitnehmer den größten Stress
Die ärmsten Länder der EU
Hier ist das BIP schlechter als im Durchschnitt
Vor diesen Berufen macht die Digitalisierung keinen Halt
Diese Jobs sind besonders stark bedroht
Diese Millionenbeträge verdienten die Sport-Stars in 2017
Diese Profis konnten ihren Kontostand 2017 deutlich verbessern
Berufe die auch eine Rezession überstehen
Welche bieten am meisten Sicherheit?
mehr Top Rankings

Umfrage

Bundeskanzlerin Angela Merkel lehnt eine Obergrenze für Flüchtlinge weiter ab. Sind Sie für eine solche Grenze?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln

Willkommen bei finanzen.net Brokerage

Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus finanzen.net

Weitere Informationen finden Sie hier.

Jetzt informieren


Sie haben bereits ein Depot? Dann verknüpfen Sie es jetzt mit Ihrem finanzen.net-Account!

Jetzt mit finanzen.net-Account verknüpfen

Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
BMW AG519000
Volkswagen (VW) AG Vz.766403
Scout24 AGA12DM8
Apple Inc.865985
BASFBASF11
Allianz840400
E.ON SEENAG99
CommerzbankCBK100
TeslaA1CX3T
Siemens AG723610
Greiffenberger AG589730
adidas AGA1EWWW
Coca-Cola Co.850663